drugset
Drugs / AJ201
last change Apr 2026 re-read 3 minutes ago

AJ201

Developed for
bulbospinal muscular atrophy · Kennedy disease
Investigated by
AnnJi Pharmaceutical Co., Ltd.

Trials 1

today NCT07549919 · Ph 1
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07549919 Apr 2026 overdue — AnnJi Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Comparator or background therapy1 trial
Phase 1/2 NCT05517603 Comparator Feb 2023 → Apr 2024 Kennedy disease, bulbospinal muscular atrophy AnnJi Pharmaceutical Co., Ltd. Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2024-05-16 Avenue Therapeutics, Inc. Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) avenuetx.com ↗
2024-01-02 Avenue Therapeutics, Inc. Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) avenuetx.com ↗
2023-07-27 Avenue Therapeutics, Inc. Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) avenuetx.com ↗
2023-03-02 Avenue Therapeutics, Inc. Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy avenuetx.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AJ201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549919 ↗
1

NCT05517603 ↗
Route Oral “Administered orally” NCT05517603 ↗